MYCN and neuroblastoma: Another study, based on the transcriptomic profiles of high-risk neuroblastoma and considering clinical and biological features, characterized three molecular subtypes of neuroblastoma: a first subtype mostly presenting with MYCN amplification, a second type with hemizygous deletions of chromosome 11q, and a third type not strongly associated with specific genomic alterations but displaying a strong mesenchymal signature [46].